Advantage Alpha Capital Partners LP Halozyme Therapeutics, Inc. Transaction History
Advantage Alpha Capital Partners LP
- $361 Million
- Q1 2025
A detailed history of Advantage Alpha Capital Partners LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 13,830 shares of HALO stock, worth $798,405. This represents 0.24% of its overall portfolio holdings.
Number of Shares
13,830
Previous 9,033
53.11%
Holding current value
$798,405
Previous $431,000
104.64%
% of portfolio
0.24%
Previous 0.11%
Shares
6 transactions
Others Institutions Holding HALO
# of Institutions
589Shares Held
122MCall Options Held
308KPut Options Held
131K-
Black Rock Inc. New York, NY17.6MShares$1.02 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$741 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$349 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$225 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$212 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.04B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...